Intellia Therapeutics stock analysis
Intellia Therapeutics (38I) Stock Price & Analysis
38I Stock Chart & Stats
- Day’s Range
- CHF 9.60 - CHF 9.60
- 52-Week Range
- CHF 8.59 - CHF 11.22
- Previous Close
- CHF 9.60
- Volume
- N/A
- Average Volume (3M)
- 17
- Market Cap
- CHF 1.12B
- Enterprise Value
- CHF 1.45B
- Total Cash (Recent Filing)
- CHF 474.11M
- Total Debt (Recent Filing)
- CHF 230.14M
- Price to Earnings (P/E)
- ―
- Beta
- 0.87
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.66
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase III Efficacy
The strong Phase III efficacy profile supports the potential for lonvo-z to deliver meaningful clinical benefits in hereditary angioedema. Durable attack reduction and freedom from ongoing therapy could differentiate a one-time treatment and strengthen Intellia’s commercial position if approval is secured.
Regulatory Momentum
BLA acceptance and Priority Review provide a defined regulatory pathway and improve visibility around a potential commercial transition. The absence of a currently planned advisory committee may reduce one source of review complexity, supporting focused launch preparation over the next several months.
Funding Runway
Substantial liquidity and a stated runway into at least 2028 give Intellia time to complete late-stage development, pursue regulatory milestones, and prepare for a potential launch without immediate dependence on product revenue. This supports strategic flexibility while programs advance.
Bears Say
Persistent Cash Burn
Large, recurring cash outflows show that Intellia’s development and commercialization activities are consuming substantial resources before product sales begin. Continued losses increase reliance on liquidity, financing, or milestone proceeds and could constrain investment choices if programs take longer to advance.
Nex-z Safety Risk
The nex-z liver enzyme signal creates a material clinical and regulatory execution risk for a key pipeline program. Monitoring, mitigation, and regulatory engagement may add complexity to development, while safety concerns could affect enrollment, treatment adoption, and the program’s eventual commercial opportunity.
Shrinking Collaboration Revenue
The sharp decline in collaboration revenue weakens a historically important funding source for this clinical-stage company. Lower partner-derived income increases the gap between operating needs and internally generated revenue, leaving Intellia more dependent on financing and future clinical or commercial milestones.
Intellia Therapeutics News
38I FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
What is Intellia Therapeutics’s market cap?
When is Intellia Therapeutics’s upcoming earnings report date?
How were Intellia Therapeutics’s earnings last quarter?
Is Intellia Therapeutics overvalued?
Does Intellia Therapeutics pay dividends?
What is Intellia Therapeutics’s EPS estimate?
How many shares outstanding does Intellia Therapeutics have?
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Intellia Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Intellia Therapeutics Stock Smart Score
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Leonard
- Employees
- 377
- Website
- www.intelliatx.com
- Address
- 400 Technology Square, Cambridge, MA, 02139, US
Intellia Therapeutics (38I) Earnings & Revenues
38I Earnings Call
Earnings Call SentimentPositive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.
View all CH:38I earnings summaries38I Net sales Breakdown
- 100.00% Collaboration revenue
38I Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 8 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 3 | 0 | 5 |














